358 related articles for article (PubMed ID: 11339897)
1. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas.
Galanis E; Bateman A; Johnson K; Diaz RM; James CD; Vile R; Russell SJ
Hum Gene Ther; 2001 May; 12(7):811-21. PubMed ID: 11339897
[TBL] [Abstract][Full Text] [Related]
2. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas.
Allen C; McDonald C; Giannini C; Peng KW; Rosales G; Russell SJ; Galanis E
J Gene Med; 2004 Nov; 6(11):1216-27. PubMed ID: 15459967
[TBL] [Abstract][Full Text] [Related]
3. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction.
Johnson KJ; Peng KW; Allen C; Russell SJ; Galanis E
Gene Ther; 2003 May; 10(9):725-32. PubMed ID: 12704411
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy for malignant glioma using Sindbis vectors expressing a fusogenic membrane glycoprotein.
Zhang J; Frolov I; Russell SJ
J Gene Med; 2004 Oct; 6(10):1082-91. PubMed ID: 15368589
[TBL] [Abstract][Full Text] [Related]
5. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.
Nanda D; Vogels R; Havenga M; Avezaat CJ; Bout A; Smitt PS
Cancer Res; 2001 Dec; 61(24):8743-50. PubMed ID: 11751394
[TBL] [Abstract][Full Text] [Related]
6. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma.
Rainov NG; Fels C; Droege JW; Schäfer C; Kramm CM; Chou TC
Cancer Gene Ther; 2001 Sep; 8(9):662-8. PubMed ID: 11593335
[TBL] [Abstract][Full Text] [Related]
8. [The construction of recombinant type I herpes simplex virus carrying GALV.fus gene and its antitumor effect in nude mice].
Zhu M; Yang JR; Jiang YQ; Chen SF; Fu XP; Tian ZD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 Mar; 42(2):152-6. PubMed ID: 21500543
[TBL] [Abstract][Full Text] [Related]
9. Fusogenic membrane glycoproteins induce syncytia formation and death in vitro and in vivo: a potential therapy agent for lung cancer.
Lin EH; Salon C; Brambilla E; Lavillette D; Szecsi J; Cosset FL; Coll JL
Cancer Gene Ther; 2010 Apr; 17(4):256-65. PubMed ID: 19893593
[TBL] [Abstract][Full Text] [Related]
10. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy.
Diaz RM; Bateman A; Emiliusen L; Fielding A; Trono D; Russell SJ; Vile RG
Gene Ther; 2000 Oct; 7(19):1656-63. PubMed ID: 11083474
[TBL] [Abstract][Full Text] [Related]
11. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy.
Higuchi H; Bronk SF; Bateman A; Harrington K; Vile RG; Gores GJ
Cancer Res; 2000 Nov; 60(22):6396-402. PubMed ID: 11103804
[TBL] [Abstract][Full Text] [Related]
12. Increased invasion of malignant gliomas after 15-LO-1 and HSV-tk/ganciclovir combination gene therapy.
Pacholska A; Wirth T; Samaranayake H; Pikkarainen J; Ahmad F; Ylä-Herttuala S
Cancer Gene Ther; 2012 Dec; 19(12):870-4. PubMed ID: 23079672
[TBL] [Abstract][Full Text] [Related]
13. Dexamethasone inhibits the HSV-tk/ ganciclovir bystander effect in malignant glioma cells.
Robe PA; Nguyen-Khac M; Jolois O; Rogister B; Merville MP; Bours V
BMC Cancer; 2005 Apr; 5():32. PubMed ID: 15804364
[TBL] [Abstract][Full Text] [Related]
14. Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer.
Tang Q; Zhang D; Wan M; Jin L
Cancer Biother Radiopharm; 2007 Dec; 22(6):755-61. PubMed ID: 18158766
[TBL] [Abstract][Full Text] [Related]
15. Purified herpes simplex virus thymidine kinase retroviral particles: III. Characterization of bystander killing mechanisms in transfected tumor cells.
Burrows FJ; Gore M; Smiley WR; Kanemitsu MY; Jolly DJ; Read SB; Nicholas T; Kruse CA
Cancer Gene Ther; 2002 Jan; 9(1):87-95. PubMed ID: 11916247
[TBL] [Abstract][Full Text] [Related]
16. In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.
Okada T; Caplen NJ; Ramsey WJ; Onodera M; Shimazaki K; Nomoto T; Ajalli R; Wildner O; Morris J; Kume A; Hamada H; Blaese RM; Ozawa K
J Gene Med; 2004 Mar; 6(3):288-99. PubMed ID: 15026990
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor effects of gene therapy with GALV membrane fusion glycoprotein in lung adenocarcinoma.
Zhu B; Yang JR; Fu XP; Jiang YQ
Cell Biochem Biophys; 2014 Jul; 69(3):577-82. PubMed ID: 24519667
[TBL] [Abstract][Full Text] [Related]
18. Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect.
Fu X; Tao L; Jin A; Vile R; Brenner MK; Zhang X
Mol Ther; 2003 Jun; 7(6):748-54. PubMed ID: 12788648
[TBL] [Abstract][Full Text] [Related]
19. [Suicide gene therapy for glioma using HSV-tk/GCV system].
Xu L; Ge K; Zheng Z
Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):353-7. PubMed ID: 10920915
[TBL] [Abstract][Full Text] [Related]
20. Protease pretreatment increases the efficacy of adenovirus-mediated gene therapy for the treatment of an experimental glioblastoma model.
Kuriyama N; Kuriyama H; Julin CM; Lamborn KR; Israel MA
Cancer Res; 2001 Mar; 61(5):1805-9. PubMed ID: 11280727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
